Cellectis has generously provided Cancer Research Institute with support for the Cancer Immunotherapy and You Webinar Series. Cellectis also supported a coordinated oncology executives panel on World Cancer Day moderated by CRI's CEO and Director of Scientific Affairs, Jill O'Donnell-Tormey.

Cellectis is a clinical-stage biopharmaceutical company developing allogeneic, gene-edited CART-cells (UCART) to fight blood cancers. 

*Immunotherapy results may vary from patient to patient.

Top